docetaxel anhydrous has been researched along with palomid 529 in 2 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (palomid 529) | Trials (palomid 529) | Recent Studies (post-2010) (palomid 529) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 25 | 1 | 21 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Biordi, L; Festuccia, C; Gravina, GL; Jannini, EA; Marampon, F; Petini, F; Sherris, D; Tombolini, V | 1 |
2 other study(ies) available for docetaxel anhydrous and palomid 529
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzopyrans; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Taxoids; Transcription Factors | 2011 |